• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Molecular Templates Inc.

    11/26/24 4:35:56 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTEM alert in real time by email
    DEFA14A 1 d782889ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

     

     

    Filed by the Registrant  ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Under Rule 14a-12

    Molecular Templates, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials:

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     


    LOGO

    MOLECULAR TEMPLATES, INC.

    9301 Amberglen Blvd., Suite 100

    Austin, TX 78729

    (512) 869-1555

    Notice of Adjournment of Special Meeting of Stockholders

    Dear Stockholder:

    The Special Meeting of Stockholders (the “Special Meeting”) for Molecular Templates, Inc. (the “Company”) held on November 26, 2024, has been adjourned to December 4, 2024 at 10:00 a.m., Eastern Time, to be held virtually via live webcast on the Internet. The close of business on October 15, 2024 will continue to be the record date for the determination of stockholders of the Company entitled to vote at the Special Meeting.

    The Proxy Statement we sent you in October 2024 contains important information regarding the proposal to approve the dissolution of the Company and the Plan of Liquidation and Dissolution that all stockholders are being asked to consider. A copy of the Proxy Statement may be viewed or downloaded by following the instructions at www.proxyvote.com. If you have any questions regarding the proposals, or need assistance with voting, you may call Alliance Advisors LLC, the Company’s proxy solicitor, toll-free at 1-973-873-7700.

    If you are the record holder of your shares, you may vote in one of four ways. You may submit a proxy to vote over the Internet, by telephone, or by mail or you may vote at the Special Meeting.

    You may submit a proxy to vote over the Internet or by telephone: Follow the instructions on the proxy card to vote by Internet or telephone.

    You may submit a proxy to vote by mail: If you received a proxy card by mail, you can vote by mail by completing, signing, dating and returning the proxy card as instructed on the card.

    You may vote during the meeting: To vote during the live webcast of the special meeting, you must first register at https://web.viewproxy.com/mtem/2024. Upon completing your registration, you will receive further instructions via email, including your unique link that will allow you access to the special meeting and to submit questions during the special meeting. Please be sure to follow instructions found on your proxy card and subsequent instructions that will be delivered to you via email.

    Telephone and Internet voting for stockholders of record will be available until 11:59 p.m. Eastern Time on December 3, 2024 and mailed proxy cards must be received by December 3, 2024 in order to be counted at the Special Meeting. If the Special Meeting is adjourned or postponed, these deadlines may be extended.

    Thank you for your prompt attention to this matter and your continued confidence in Molecular Templates, Inc. If you have already voted, we appreciate your participation, and you may disregard this notice.

    Sincerely,

    Harold E. “Bary” Selick, Ph.D.

    Chairman of the Board of Directors

     

    1

    Get the next $MTEM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTEM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEM
    SEC Filings

    View All

    SEC Form 8-K filed by Molecular Templates Inc.

    8-K - Molecular Templates, Inc. (0001183765) (Filer)

    1/2/25 4:13:52 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Molecular Templates Inc.

    8-K - Molecular Templates, Inc. (0001183765) (Filer)

    12/19/24 4:11:29 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Molecular Templates Inc.

    DEFA14A - Molecular Templates, Inc. (0001183765) (Filer)

    12/4/24 4:10:56 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Biotech Target N V sold $845,833 worth of shares (1,279,820 units at $0.66), closing all direct ownership in the company (SEC Form 4)

    4 - Molecular Templates, Inc. (0001183765) (Issuer)

    11/18/24 9:12:24 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lalande Kevin M.

    4 - Molecular Templates, Inc. (0001183765) (Issuer)

    9/30/24 5:41:36 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Gruia Gabriela

    4 - Molecular Templates, Inc. (0001183765) (Issuer)

    9/30/24 5:37:40 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTEM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

    Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

    5/14/25 4:30:00 PM ET
    $CLDI
    $MTEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

    SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

    4/23/25 8:00:00 AM ET
    $CLDI
    $MTEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules

    AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or the "Company")), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, was notified on December 16, 2024 by the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") of the Staff's determination pursuant to Nasdaq Listing Rule 5101 that the Company is a "public shell," and that, in the view of the Staff, the continued listing of the

    12/19/24 4:10:00 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $MTEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    BofA Securities initiated coverage on Molecular Templates with a new price target

    BofA Securities initiated coverage of Molecular Templates with a rating of Buy and set a new price target of $12.00

    4/21/21 6:52:47 AM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Molecular Templates with a new price target

    UBS initiated coverage of Molecular Templates with a rating of Neutral and set a new price target of $13.00

    2/1/21 7:51:02 AM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biotech Target N V bought $587,500 worth of shares (250,000 units at $2.35), increasing direct ownership by 24% to 1,279,820 units (SEC Form 4)

    4 - Molecular Templates, Inc. (0001183765) (Issuer)

    4/4/24 8:13:35 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTEM
    Leadership Updates

    Live Leadership Updates

    View All

    Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

    Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

    5/14/25 4:30:00 PM ET
    $CLDI
    $MTEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

    SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

    4/23/25 8:00:00 AM ET
    $CLDI
    $MTEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

    AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the appointment of Dr. Maurizio Voi to the role of Chief Medical Officer. Dr. Voi possesses more than 35 years of wide-ranging drug development experience. Dr. Voi will begin his new role on October 2, 2023. Dr. Voi joins MTEM from Novartis, where he served as Vice President, Global Program Head, for the PD-1 antibody Tislelizumab since April 2021. He was previously Global Program Head, Melanoma, at Novartis, a pos

    9/28/23 4:11:00 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

    SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

    11/18/24 9:49:56 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

    SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

    11/14/24 4:37:56 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

    SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

    11/12/24 9:31:46 AM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care